

Table 1A

Relationship between FDG uptake and clinicopathologic findings

FDG uptake by the primary tumor						
Factors	Total	Negative (n=45)		Positive (n=35)		p
		No.	%	No.	%	
Gender						
Male	72	43	59.7	29	40.3	0.0700
Female	8	2	25.0	6	75.0	
Tumor Location						
Upper	9	4	44.4	5	55.6	0.9120
Middle	38	18	47.4	20	52.6	
Lower	33	17	51.5	16	48.5	
Histology						
Well	25	21	84.1	4	16.0	0.0020
Moderate	47	21	44.7	26	55.3	
Poor	8	3	37.5	5	62.5	
Depth of tumor invasion						
M1	10	10	100.0	0	0.0	< 0.0001
M2	11	9	81.8	2	18.2	
M3	8	7	87.5	1	12.5	
SM1	11	9	81.8	2	18.2	
SM2	8	4	50.0	4	50.0	
SM3	32	6	13.3	26	86.7	
Lymph node metastasis						
N0	64	42	65.6	22	34.4	0.0006
N1	16	3	18.6	13	81.4	
Lymphatic invasion						
negative	61	40	65.6	21	34.4	0.0020
positive	19	5	26.3	14	73.7	
Vascular invasion						
Negative	56	39	69.4	17	30.6	0.0002
Positive	24	6	25.0	18	75.0	
Glut-1 expression in cell membrane						
Negative	56	39	69.4	17	30.6	0.0002
Positive	24	6	25.0	18	75.0	

Table 1B

Relationship between SUV-max value and clinicopathologic variables in FDG uptake positive patients

Parameter	n	SUV max (average)	p
Depth of tumor invasion			
SM2,3	30	5.64±0.49	0.035
M,SM1	5	3.62±1.21	
Histology			
Poor	5	5.86±1.24	0.6
Mod/Well	30	5.27±0.51	
Lymph node metastasis			
Positive	13	5.86±1.24	0.06
Negative	22	5.27±0.51	
Lymphatic invasion			
Positive	14	5.42±0.74	0.2
Negative	21	5.30±0.61	
Vascular invasion			
Positive	18	5.98±0.64	0.085
Negative	17	4.68±0.66	
Glut-1 expression in cell membrane			
Positive	30	5.49±0.51	0.63
Negative	5	4.56±1.24	